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TB and the HIV-Positive Prisoner
Rachel Maddow*^, Andrew Vernon, MD, MHS**^,
Carol J. Pozsik, RN, MPH***^

There is a perilous synergy between HIV and
tuberculosis in correctional facilities. Prisoners,
who have long been known to have disproportionately high rates of diagnosed TB disease
and TB infection,1 (See Figure 1) also have
more than 5 times the general population's rate
of AIDS, and between 4 and 10 times the general population's rate of HIV infection.2
Crowding, poor ventilation, the high prevalence
of HIV among prisoners, and the higher prevalence of TB in the communities from which prisoners are disproportionately drawn can make
correctional facilities key sites of amplification
for TB transmission. This article will review the
interactions between HIV and TB in correctional settings, describe a recent outbreak of TB in
a facility where HIV-infected inmates are segregated, and address the treatment of TB in HIVinfected individuals.

The Broad River Outbreak

During the Spring of 2000, South Carolina
reported a significant TB outbreak among HIVpositive prisoners.3 Contemporaneously, the
Institute of Medicine released a report on the
lamentable state of TB eradication,4 and the
CDC released updated guidelines for simultaneous treatment of HIV and TB5 and new guidance on targeted screening and treatment of
latent TB infection.6 The South Carolina outbreak serves as a compelling reminder that this
emphasis on guidelines and standards for TB in
prisons and jails is well justified.
In August 1999, two men who had been housed
on the HIV-segregation unit in the Broad River
Men's Correctional Institution in Columbia,
South Carolina were diagnosed with sputum
smear-positive pulmonary tuberculosis.7 The
first patient had a previously documented tuberculin skin test reaction of 15 mm in 1984 and
two subsequent incomplete attempts at isoniazid prophylaxis. Six weeks before his TB diagnosis, in July 1999, he was admitted to a community hospital with fever, abdominal pain, and
cough. The patient's chest radiograph was normal and, despite existing guidelines for the
treatment of HIV-infected, PPD positive individuals (See HEPP News March 2000, and
Prevention and Treatment of Tuberculosis
Among Patients Infected with Human
Immunodeficiency Virus: Principles of Therapy
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Figure 1. Prisoners among US TB cases
and US residents, 1999. In 1999, prisoners
made up 0.73% of US residents, but they
made up 3.3% of all US TB cases.
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and Revised Recommendations, MMWR 1998;
47(No. RR-20):1-58), no sputum specimens
were obtained for AFB smear and culture. He
was not placed in respiratory isolation and was
returned to the prison. Six weeks later, in midAugust, the patient returned to the community
hospital, where he was diagnosed with active
TB. Later that month, South Carolina
Department of Corrections (DOC) staff learned
that another prisoner who had been released
from the same HIV-segregation unit in July
1999 had been diagnosed with active TB.8
The SC DOC and the state's Department of
Health and Environmental Control initiated a
contact investigation, and invited collaboration
from the Centers for Disease Control and
Prevention. Contact investigators tracked down
current prisoners who had come into contact
with the source case-patient (he had participated in congregate religious activity, including
bible study),9 as well as more than 100 prisoners who had lived in the source-case patient's
dormitory but had since been released into the
community. By the time CDC reported on the
investigation in November 2000,10 over 320
current or former inmates from the HIV-segregation unit were found to have been exposed to
MTB and 31 were diagnosed with TB disease.
Continued on page 2
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(continued from page 1)

In addition, a medical student who had
examined the initial source case-patient in
the community hospital in July developed
cavitary TB. Notably, IS6110-based DNA
fingerprints of all 20 available outbreakassociated M. tuberculosis isolates were
identical.11

Repeating History

Although the South Carolina outbreak was
due to a drug-susceptible strain of TB, it
was a reminder of the deadly 1990-1991
outbreak of multi-drug-resistant TB in New
York prisons and jails.12 Of the 39 New
York inmates identified with MDR-TB, 38
were HIV-positive.13 As an airborne infection, TB presents one of the most immediate health threats not only to prisoners, but
also to correctional staff, health care
providers, visitors, and others who come in
close contact with TB patients.
The single most potent factor affecting the
risk of progression from latent TB infection
to active TB disease is HIV coinfection.14 It
is often more difficult to detect active TB in
persons with HIV/AIDS because they may
not respond to the tuberculin skin test, and
they may present atypical or negative findings on chest x-ray.15 Furthermore, significant drug interactions may complicate the
concurrent treatment of HIV and TB.16 In
short, HIV increases the risk of progression
from TB infection to disease, makes
screening for TB more difficult, and complicates the treatment of TB. (Refer to
HEPPigram on page 6.)
For New York State, the 1990-1991 outbreak was a catalyst for overhauling the
DOC's anti-TB efforts. TB protocols were
modified to reflect heightened levels of
scrutiny for HIV-infected individuals who
might be harboring TB. Stepped-up monitoring and treatment resulted in a 73%
decrease in the NYDOC's TB incidence
rate (per 100,000 population) from 225 in
1991 to 61 in 1997.17

Think TB! Screening and
Treating prisoners
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As recommended by the National
Commission for Correctional Health Care,
all prisoners should receive tuberculosis
symptom screening on intake; anyone with
TB symptoms (chronic productive cough,
fever, weight loss, night sweats) should
immediately be moved to a negative pressure respiratory isolation room and evaluated for TB disease. Tuberculin skin tests
(TST) should be administered to all prisoners who have not had a previous documented positive skin test result. A TST
reaction (induration at 48-72 hours) of
greater than 10mm should be taken as
indicative of TB infection in HIV-negative
prisoners; however, in HIV-infected individ-

Table 1. Treating Latent TB Infection in HIV-Positive Patients*
DRUG

REGIMEN

INH

Daily for 9 months

INH

isoniazid

2 x / week
for 9 mos

RIF

Daily for 2 months

isoniazid

rifampin

+
PZA

CRITERIA FOR COMPLETION

DOSAGE
5 mg/kg (adults) up to
300 mg
15 mg/kg (adults) up to
900 mg

= 270 doses w/in 12 mos

RIF 10 mg/kg (adults)
(600mg) PZA 15-20
mg/kg (adults) (2g)

Alternate regimen for HIV+
(and HIV-) adults
DOT MUST BE USED**

= 76 doses w/in 12 mos
DOT MUST BE USED**

pyrazinamide
*adapted from the New Jersey Medical School National TB Center (NTBC) pocket guide. To
obtain call 973-972-3270.
** DOT is always preferred in prison and jail settings. With 2x weekly dosings DOT must be used.

uals and in recent contacts of an active
case, the threshold is only 5mm. Any
patient whose TST indicates TB infection,
and all HIV-positive patients, should
receive a chest x-ray. It should be noted
that TST may fail to identify TB infection in
high-risk patients including prisoners.18 TB
control officers may consider using on-site
chest radiography to screen all prisoners
at entry (see HEPP News March 2000).
HIV-positive patients with TB may be unresponsive to TST19 - and even chest xrays may fail to demonstrate abnormalities
in HIV-positive patients with TB disease. It
is therefore recommended that any HIVpositive patient with respiratory symptoms
undergo a sputum analysis in addition to a
chest x-ray.
Prisoners with documented latent TB infection (LTBI) should complete a course of
treatment.20 Several regimens are currently recommended; for HIV-positive patients
not taking HAART, guidelines for treating
latent TB infection are substantially similar
to those for persons who are HIV-negative
(see Table 1).
Those with a positive TST who cannot
complete treatment for latent TB infection
(LTBI) should receive regular screening for
TB symptoms (South Carolina's TB Control
Division recommends quarterly screening);
any such patient with significant immune
suppression should be scrutinized for TB
symptoms even more frequently. Prisoners
who clear the initial TB intake screening
should be evaluated at least yearly for TST
conversion, and more frequently if there is
evidence of recent transmission of TB in
the facility or if prisoners with HIV are
housed together.21

Treating Active TB in the
HIV-Positive Patient

HIV-positive persons with active TB are
always candidates for HAART (if not
already on HAART) since active TB infection is itself an AIDS-defining illness. While
it may sometimes be feasible to delay
HAART treatment in order to start treatment for TB disease, the converse is not

true: there is no clinical justification for
delaying the treatment of active TB.
The complicated nature of coadministering
treatment for active TB and HAART is due
to the fact that the rifamycin drugs used to
treat TB (usually rifampin or rifabutin) stimulate the same liver enzyme systems
(CYP450) that process protease inhibitors
(PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).22 Non-rifamycin
TB drugs (such as isoniazid) do not generally interact with HAART medications.
However, treatment of active TB in HIVpositive persons using regimens lacking a
rifamycin is regarded as sub-optimal and is
not recommended.23 CDC guidelines for
the concurrent treatment of HIV and TB
were updated in March 2000.24 Previous
guidelines had advised that rifampin not be
administered to an HIV-positive patient taking any PI or NNRTI, but the update advises that rifampin can probably be co-administered with these three HAART regimens:
(1) when HAART includes the NNRTI
efavirenz and two NRTIs.
(2) when HAART includes ritonavir and
one or more NRTIs, and
(3) when HAART includes a combination
of ritonavir and saquinavir (either hard gel
or soft gel).
(Data were also presented at the 8th
Retroviruses Conference in Chicago in
February suggesting that it may be necessary to increase efavirenz dosage to 800
mg/qd when used in combination with
rifampin. See HIV 101, page 7 for a complete chart of dosages).25
In addition, the CDC had previously recommended that rifabutin could safely be used
with any PI other than ritonavir and any
NNRTI other than delavirdine. The new
recommendations advise that rifabutin may
be co-administered with ritonavir (with or
without saquinavir), but that the dosage of
rifabutin should be reduced substantially to
150 mg two or three times per week. While
there are not substantial clinical data on the
subject, the CDC recommends that it is
possible to administer rifabutin with the PIs
Continued on page 4
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Letter from the Editor
Dear Colleagues,
HIV infection is relatively difficult to acquire, but its frequent co-infection, TB, is acquired by
the simple act of breathing. And, when we are doing our breathing in a congregate setting,
such as a prison or jail, we and our families can be at risk. That is why aggressive TB control in corrections is critically important not only to corrections but also to our communities.
New York State Department of Correctional Services (NYSDOCS) conducts a TB skin test
on everyone in our system at least every year, and has a high index of suspicion for TB.
Approximately 25% of the inmates we receive have TB infection. We require that any time
sputum testing for AFB is done, it must take place in negative pressure and the patient must
be isolated at least until three negative smear results are available (or until cultures have
returned if the patient has symptoms). Thus we have a presumption of TB until proven otherwise. At the NYSDOCS, we believe that in our setting, and with our history as a system,
if we are concerned enough to get sputums for AFB we should be concerned enough to isolate until we know the results. The majority of our inmates come from New York City and
many have risk factors for developing TB disease. In the 10 years that we have been taking TB so seriously we have seen incidence of TB disease in our system decrease from
225/100,000 to 26/100,000. This is approximately the TB incidence rate of Manhattan!
Since we give all TB medications, both for treatment and for prophylaxis, by directly
observed therapy, we have seen a major decrease in MDR disease; with only one case in
the last two years.
HIV 101 this month covers interactions between antiretrovirals and rifamycins. The
HEPPigram is an algorithm for managing a positive PPD skin test on routine screening. In
our "Ask the Expert" piece, Dr. Jane Carter of Rhode Island discusses a case of active
tuberculosis in a patient recently diagnosed with HIV. After reviewing this issue, readers
should be able to describe the best management for TB cases in corrections, choose a suitable regimen for co-administering HIV and TB medications, and list some of the challenges
presented in the treatment of co-infection.
Next month we'll bring you the latest on Hepatitis C treatment and management. Feel free
to write us with questions or suggestions on how we can be a better resource!
Sincerely,

The editorial board and contributors to HEPP
News include national and regional correctional
professionals, selected on the basis of their
experience with HIV care in the correctional
setting and their familiarity with current HIV
treatment. We encourage submissions, feedback, and correspondence from our readership.

Lester Wright, MD
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TB and the HIVPositive Prisoner...
(continued from page 2)

saquinavir, nelfinavir, or amprenavir and the
NNRTI nevirapine without reducing the
dosage of rifabutin. Rifabutin should not be
used with the NNRTI delavirdine. When
rifabutin is used concurrently with the NNRTI
efavirenz, the dosage of rifabutin should be
increased (to either 450 mg or 600 mg daily
or 600 mg two or three times per week).
The exact appropriate dosages of the
rifamycins (either rifampin or rifabutin) may
vary depending on the exact HAART medications and dosages (See HIV 101, page 7).
In HAART regimens that contain multiple PIs
or PI/NNRTI combinations, there is little clinical experience and no firm guidance from
CDC; state health authorities and experts in
HIV/TB coinfection should be consulted.
Updated guidelines and information on TB
diagnosis and treatment can always be
found on the CDC's Division of TB
Elimination website: http://www.cdc.gov/nchstp/tb.

Other drug cautions for
TB treatment

It should also be noted that two non-HAART
drugs commonly administered to HIV-positive patients, fluconazole and clarithromycin,
both cause an increase in rifabutin levels.
Both fluconazole and clarithromycin cause
this effect independently, and the effect is
more-than-doubled when both are present.
Clinicians should monitor for rifabutin toxicity
(arthralgia, neutropenia, uveitis) when coadministering fluconazole and/or clarithromycin.26
Any patient taking isoniazid or pyrazinamide
should be cautioned about hepatotoxicity
and monitored for its symptoms, which can
include nausea, vomiting, jaundice, abdominal pain, and anorexia. The risk of hepatotoxicity is probably greater in persons with
acute hepatitis, chronic liver disease, injecting drug use history, prior intolerance of
either medication, chronic alcoholism, or current use of interacting medications.
Correctional clinicians should obtain baseline hepatic measurements of serum AST
(SGOT) or ALT (SGPT) and bilirubin before
starting therapy for TB infection, and may
need to consider more frequent monitoring of

*HEPP News Staff Writer
**Supervisory Medical Epidemiologist, Research and Evaluation Branch, Project
Officer, TB Trials Consortium, Division of TB Elimination, NCHSTP, CDC
***Director, TB Control Division, SC Department of Health and Environmental
Control
^Nothing to disclose.

REFERENCES:

1.CDC. Prevention and control of tuberculosis in correctional facilities: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR
1996; 45(No. RR-8):2.
2.Hammett, TM; Rhodes, W; Harmon P 'HIV/AIDS and Other Infectious
Diseases Among Correctional Inmates: A Public Health Problem and
Opportunity' National HIV Prevention Conference 1999. Atlanta, GA. Abstract
571.
3.CDC. Drug-susceptible Tuberculosis Outbreak in a State Correctional Facility
Housing HIV-Infected Inmates - South Carolina, 1999-2000. MMWR 2000;
49(46):1041-4. Spradling P, McLaughlin S, Drociuk D, et al 'Transmission of
mycobacterium tuberculosis among inmates in an HIV-dedicated prison dormitory' XIII International AIDS Conference 2000. Durban, South Africa. Abstract
ThPeB5188.
4.Institute of Medicine. Ending Neglect: The Elimination of Tuberculosis in the
United States. Washington, DC: National Academy Press. 2000.
5.CDC. Notice to Readers: Updated Guidelines for the Use of Rifabutin or
Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected
Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase
Inhibitors. MMWR 2000; 49(09):185-9.
6.CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49(No. RR-6):1-51.
7.American Health Consultants 'TB plus HIV cause big trouble for prison, jail in
two Southern states' TB Monitor 2000; 7(8):77-79.
8.CDC. Drug-susceptible Tuberculosis Outbreak in a State Correctional Facility
Housing HIV-Infected Inmates - South Carolina, 1999-2000. MMWR 2000;
49(46):1041-4.
9.American Health Consultants 'TB plus HIV cause big trouble for prison, jail in
two Southern states' TB Monitor 2000; 7(8):77-79.
10.CDC. Drug-susceptible Tuberculosis Outbreak in a State Correctional
Facility Housing HIV-Infected Inmates - South Carolina, 1999-2000. MMWR
2000; 49(46):1041-4.
11.CDC. Drug-susceptible Tuberculosis Outbreak in a State Correctional Facility
Housing HIV-Infected Inmates - South Carolina, 1999-2000. MMWR 2000;
49(46):1041-4.
12.CDC. Transmission of Multidrug-Resistant Tuberculosis Among
Immunocompromised Persons in a Correctional System - New York, 1991.
MMWR 1992; 41(28):507-9.
13.Valway SE, Greifinger RB, Papania M, et al 'Multidrug-resistant tuberculosis

4

clinical and/or biochemical status when
either medication is used in treating latent TB
infection. A forthcoming report (MMWR, April
2001) from the CDC will give additional data
on serious adverse reactions associated with
treatment for latent TB infection. Adverse
reactions to a two month regimen of rifampin
and pyrazinamide can be serious or even
fatal, and patients should be monitored
closely for liver toxicity. For additional information on optimal monitoring approaches,
providers may wish to access information
provided at the National TB Center
TB
Infoline
1-800-4TB
DOCS
or
http://www.umdnj.edu/ntbc.

Conclusion

Two maxims are critical to TB control in correctional settings: "Think TB!" and "Consult
an expert". TB specialists are available
through the departments of public health in
every state, and CDC experts are available
for additional consultation. All it takes to
transmit TB is to share airspace with an
active TB case. Correctional providers and
staff are also at risk when active TB is present in a prison or jail setting.
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Double Trouble in Guantanamo Bay

by Jane Carter, M.D.*Clinical Assistant Professor of Medicine, Division of Infectious Disease, Pulmonary and Critical Care, Brown University
Medical Director, TB Clinic of Rhode Island

CASE:

A 46-year-old Haitian gentleman presented to the general medical clinic at Guantanamo Bay for evaluation of fevers. He
speaks only Haitian Creole. He denies all localizing symptoms,
specifically headache, cough, sputum production, dysuria, diarrhea or myalgias. Chest radiography (CXR), blood work, and
cultures are normal. A diagnosis of viral syndrome was made.

DISCUSSION:

The initial institution of four drug therapy in treating TB is recommended if the local rate of INH resistance is >4%. The four
drug regimen prevents the development of further resistance by
guaranteeing that the patient is being treated with at least two
drugs to which the organism is susceptible.

If, however, there is an epidemiologic risk that the patient may
have higher grade primary resistance, more than four drugs
should be utilized. INH resistance rates are reported to be at
least 25% in Haiti; resistance patterns of other drugs are not
available. The IUATLD/WHO resistance study in 1995 did look
at the Dominican Republic which shares the same island as
Haiti. In the DR INH resistance is 20%; Rifampin
When TB and HIV resistance is 16%; Streptomycin resistance is
30%. In addition this patient lived in NYC during
are simultaneously the increased incidence of both TB and MDR TB.
Thus, a five-drug regimen was initially utilized to
diagnosed, a
ensure adequate coverage pending susceptibility
decision must be
patterns.

Two weeks later he returns continuing to complain of fever.
Physical examination reveals a temperature of 105.5 degrees
and enlarged right cervical lymph node. His CXR is repeated,
demonstrating a faint left upper lobe infiltrate that was, in retrospect, present on the previous film.
He is admitted to the hospital and started on broad
spectrum antibiotics for outpatient acquired pneumonia. Sputum samples were obtained, he was
3+AFB smear positive. He was started on
Isoniazid (INH), Rifampin, Pyrazinamide (PZA),
Ethambutol and Capreomycin.
Drug susceptibility testing for his TB isolate
returned demonstrating a fully susceptible organism. Capreomycin and Ethambutol were discontinued. On TB treatment, his lymph nodes regressed
in size. Fevers disappeared. His sputum reverted
to smear negative. After he was noted to have
acute hepatitis A, PZA was dropped from his regimen to decrease the risk of hepatotoxic reactions.

made whether to
initiate therapy for
both diseases
simultaneously or
in parallel.

During his initial visits in the clinic he denied being HIV positive
or having risk factors for HIV. His initial CD4 was 200, viral load
10,000. After he tested positive for HIV, he refused to accept his
diagnosis. One month into therapy he developed headaches
and confusion. He appeared acutely ill with a fever of 104.5
degrees. He was hospitalized and LP demonstrated cryptococcal meningitis. Amphotericin and 5 flurocitabine were initiated.
Fevers defervesced and his mental status cleared.
Due to the appearance of a second OI it was felt necessary to
institute antiretroviral therapy. Efavirenz (Sustiva), stavudine
(d4T, Zerit) and lamivudine (3TC, Epivir) were begun. Following
last years CDC TB treatment guidelines Rifampin was changed
to Rifabutin to decrease the possibility of drug-drug interactions.
Ethambutol was reintroduced to strengthen his anti-TB regimen.
Within a week he again started spiking high fevers. A full evaluation was initiated including CT of the chest and abdomen as
well as bone marrow biopsy. No new source of fever was identified. Prednisone therapy was started to treat an immune
reconstitution syndrome. DOT of anti-TB medications was continued.
His TB medications were continued for a total of 9 months, during which time he gained 30 pounds. Lymphadenopathy
regressed. Chest radiograph cleared. Viral load dropped to a
nondetectable level.
*Consultant, RI Dept. of Health

When TB and HIV are simultaneously diagnosed,
a decision must be made whether to initiate therapy for both diseases simultaneously or in parallel.
The decision to treat TB cannot be delayed. Time
from infection to death from TB disease in
advanced HIV has been demonstrated to be as
short as 20 weeks. In addition it has been noted
that treating TB in co-infected individuals can raise CD4 counts
and decrease viral load. Institution of concomitant or delayed
therapy of HIV must be individualized. In this patient TB treatment was immediately instituted while HIV therapy was
delayed. This decision was made for a variety of factors including the fact that the patient would not initially believe he had
HIV, making his willingness to comply with HIV therapy unlikely.
In addition rifampin, one of most powerful antituberculous
drugs, cannot be utilized with NNRTIs or PIs. Whenever possible, rifampin is included in the first two months of TB therapy to
improve rapid response.
The development of a second OI (the first OI was TB) changed
this situation. Antiretrovirals were instituted, which did necessitate a change in rifamicin use for TB. Reconstitution of the
immune system allowed for a dramatic inflammatory response
to the patient's TB disease, resulting in a clinical picture of high
fevers. Note that immune reconstitution syndrome is a diagnosis of exclusion.
Systemic steroids may be utilized to treat the symptoms of this
phenomenon with tapering over 4-6 weeks.
Mistrust, suspision and fear clearly delayed this patient's diagnosis and affected his early care. Difficulties in his native country led him to pursue a risky escape to the US where he was
detained for one year before receiving refugee status. These
experiences resulted in mistrust and fear of authority figures.
These issues were overcome by a consistent message from his
health care providers regarding his care and prognosis. All of
these interventions resulted in a good outcome for this gentleman presenting with a constellation of complex, life-threatening
conditions.
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Management of a Positive PPD Skin Test

The following is one approach to the incarcerated patient with a newly positive PPD skin test* on routine screening, regardless of HIV status. This algorithm represents an aggressive approach, appropriate to the correctional setting because of:
1) congregate living environments, which facilitate the rapid spread of MTB;
2) the high prevalence of HIV, much of which is undiagnosed.

Symptomatic**

Asymptomatic

Mask patient and obtain same day chest x-ray.

Obtain chest x-ray.

Normal chest x-ray.

Newly abnormal *** chest x-ray consistent
with MTB, or abnormal chest x-ray
consistent with MTB and no old films
to compare.

Normal chest x-ray.

Isolate patient.
Send 3 sputum for AFB smear
and culture. Evaluate for other
causes of symptoms. If smear
is negative, prophylax for
latent TB infection.

Isolate patient.
Send 3 sputum for AFB smear and
culture. Evaluate for and treat other
etiologies. Consider beginning 4 drug
antitubercular regimen while
awaiting sputum results.

Prophylax for latent
TB infection.

*Positive PPD Skin Test is:
G >5mm for HIV + patient.
G >10mm for HIV- patient.
G an increase of >5mm from a prior PPD skin test.
G >5mm if patient has a history of TB contact.
**Symptoms include hemoptysis, cough, fever , weight loss, and night sweats.
***Classically, MTB presents with apical infiltrates. In those with HIV infection, the chest x-ray may be normal, or reveal mediastinal
adenopathy, or middle/lower lobe infiltrates.

CME is Now Available Online at www.hivcorrections.org:

HEPP readers are now able to take HEPP News' continuing medical education (CME) tests online at
http://www.HIVcorrections.org. Any internet browser will enable you to take the HEPP News CME tests every month.
Your test results will be registered with the Brown Medical School Office for Continuing Medical Education. When you
pass the test, you can either download your CME certificate from the website or request Brown to send the certificate in
the mail. Try it out this week!

HIV 101
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Interactions between HIV Medications and Rifamycins
Antiretroviral

Rifampin (RIF)

Rifabutin (RFB)

All NRTIs (AZT, 3TC,
ddI, ddC, d4T, abacavir)

No significant interaction

No significant interaction

Nevirapine (NVP)
Viramune

NVP $37%
Not recommended

NVP $16%
No dose change

Delavirdine (DLV)
Rescriptor

DLV $96%
Contraindicated

DLV $80%, RFB #100%
Not recommended

Efavirenz (EFV)
Sustiva

EFV $25%
Possibly #EFV dose to 800mg qd

RFB $35%
Dose change: #RFB to 450-600 mg qd or
600 mg 2-3x/week

Ritonavir (RTV)
Norvir

RTV $35%
Dose change: limited data, but probably
no change.

RFB #400%
Dose change:

Saquinavir (SQV)
Invirase/Fortovase

SQV $84%
Contraindicated for either Invirase or
Fortovase, unless using RTV+SQV,
then dose RIF 600 mg qd or 2-3x/wk

SQV $40%
Dose change: contraindicated for Invirase;
no adjustment needed for Fortovase,
unless using RTV+SQV (with either
Invirase or Fortovase), then dose
RFB 150 mg 2-3x/week

Nelfinavir (NFV)
Viracept

NFV $82%
Contraindicated

NFV $32%, RFB #200%
Dose change: $RFB to 150 mg qd or
300 mg 2-3x/week,
#NFV dose to 1000 mg tid

Indinavir (IDV)
Crixivan

IDV $89%
Contraindicated

IDV $32%, RFB #200%
Dose change: $RFB to 150 mg qd or
300 mg 2-3x/week,
#IDV to 1000 mg tid

Amprenavir (AMP)
Agenerase

APV $82%
Contraindicated

APV $15%, RFB #193%
Dose change: $RFB to 150 mg qd or
300 mg 2-3x/week

Lopinavir/Ritonavir (LPV)
Kaletra

LPV $75%
Contraindicated

RFB #300%
(25-O-desacetyl metabolite #47.5x)
Dose change: $RFB to 150 mg qd

$RFB to 150 mg 2-3x week.

Sources: Adapted from Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, Department of Health and and
Human Services. February 5, 2001: Table 17; and from CDC. Notice to Readers: Updated Guidelines for the Use of Rifabutin or Rifampin for
the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse
Transcriptase Inhibitors. MMWR 2000; 49(09):Table 1.

Websites
TB Websites:

National Center for HIV,STD, and TB Prevention
http://www.cdc.gov/nchstp/tb/
National Tuberculosis Controllers Association
http://www.ntca-tb.org/
Report from the 38th IDSA: Tuberculosis and HIV, by T. R. Sterling, MD
http://www.hopkins-aids.edu/publications/report/nov00_2.html
American Lung Association TB website
http://www.lungusa.org/diseases/lungtb.html
American Thoracic Society
http://www.thoracic.org
New Jersey Medical School National Tuberculosis Center
http://www.umdnj.edu/ntbcweb/
Brown University's TB/HIV Research Laboratory
http://www.brown.edu/Research/TB-HIV_Lab/

World Health Organization Global Tuberculosis Program
http://www.who.int/gtb/

HIV Treatment Websites:

HIV/AIDS Treatment Information Service
http://www.hivatis.org
HIV Insite
http://hivinsite.ucsf.edu/
AEGiS: the largest HIV/AIDS resource on the internet
http://www.aegis.com
The Body: An AIDS and HIV information Resource
http://www.thebody.com
Medscape's Infectious Disease Site
http://id.medscape.com/
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Save the
Dates
TB Dates:

Latent TB Infection: The Hidden
Threat in Our Commuity
San Diego, California
May 5, 2001
Sponsor: American Lung Association
of San Diego/Imperial Counties.
Contact: American Lung Association
Call: 619.297.3901
Email: info@lungsandiego.org
CME and CEU credits available
Advisory Council for the
Elimination of Tuberculosis
Atlanta, Georgia
July 11-12, 2001
Call: Paulette Ford at 404.639.8008
Email: pbf7@cdc.gov

More Dates:

3 Day HIV Minifellowship for
Correctional Health Care Providers
UTMB at Galveston & Correctional
Managed Care
April 23 - 25 and May 21 - 23, 2001
CME credit available
Course fee $200.00
Call: Penny Welsh at 409.747.8769
Fax: 409.747.8771
Email: pwelsh@utmb.edu
Management of HIV/ AIDS in the
Correctional Setting: A Live
Satellite Videoconference Series
"Management of the HIV/
Hepatitis C Co-infected Patient"
June 5, 2001
12:30-3:30 p.m. EST
CME Credits Available through
Albany Medical Center.
Call: 518.262.4674
Email: rosentjh@mail.amc.edu
Visit: www.amc.edu/patient/HIV/
hivconf.htm
Infectious Disease Society of
America: 39th Annual Meeting
San Francisco, California
October 25-28, 2001
Abstract deadline: May 22, 2001
Late deadline: August 20, 2001
Discounted registration deadline:
July 30, 2001
Fax: 703.299.0204
Visit: www.idsociety.org
The 5th Annual HIV Update:
Contemporary Issues in
Management
Cambridge, Massachusetts
May 31-June 2, 2001
Call: 617.432.1525
Fax: 617.432.1562
Email: hms-cme@hms.harvard.edu
Visit: http://134.174.17.108/contedbin/hmscme
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News Flashes
Drug Resistant TB on the rise among
Foreign-Born persons in the US
A December 2000 JAMA study suggests that
TB-infected foreign-born persons are bringing
isoniazid-resistant strains of TB into the
United States. Researchers from the National
Center for HIV, STD, and TB Prevention at
the CDC analyzed data from case reports
submitted to the CDC's national TB surveillance system from 1993 to 1998. Dr.
Elizabeth Talbot and colleagues predict that
more than half of TB cases in the US may
occur among foreign-born people by the year
2002. (Talbot E, Moore M, McCray E, Binkin
N. JAMA, 2000; 284: 2894-2900.)
Serostatus Approach to Fighting the
Epidemic (SAFE)
At the recent 8th Conference on Retroviruses
and Opportunistic Infections, the Centers for
Disease Control and Prevention (CDC)
announced a new national approach to providing HIV prevention services, the
Serostatus Approach to Fighting the
Epidemic (SAFE). The goal of SAFE is to
raise the importance of focused prevention
efforts to ensure early knowledge of HIV
infection, and expand prevention support and
treatment for persons living with HIV. By
increasing the number of people getting tested, enrolled in primary care programs, and
committed to state of the art HIV treatment,
SAFE hopes to reduce HIV transmission
rates by 50% by the year 2004 (from 40,000
new infections per year to 20,000). Robert
Janssen, MD, Division Director of the
National Center for HIV/AIDS, STDs and TB
Prevention's (NCHSTP) Division of HIV/AIDS
Prevention, has stated that correctional populations would be important intervention sites
for SAFE's programs. (For more information
on SAFE, contact Karina Krane, 404-6398862).
HIVMA's New Requirements for HIV
Specialists
The HIV Medicine Association (HIVMA), a
division of The Infectious Diseases Society of
America, has developed requirements for

physicians seeking to become qualified in the
treatment of patients with HIV. HIVMA hopes
that their regulations will ensure that patients
with HIV disease receive the highest quality
of care, reflecting current medical research,
at the hands of those who have demonstrated experience and commitment to treating
this disease. While HIVMA does not require
HIV-qualified physicians to be of a specific
medical discipline, the group does stipulate
that a physician must have managed at least
25 patients with HIV infection in the last year
and have spent at least 15 hours on HIVrelated continuing medical education.
Recently trained, certified, or recertified infectious disease specialists are also considered
qualified providers. (For more information,
visit the HIVMA site at: http://www.hivma.org)
Prison Health Services to take over Health
Care in New York City Corrections
On January 1 of this year, Prison Health
Services (PHS), one of the nation's largest
profit-making providers of inmate medical
care, replaced St. Barnabas Medical Center
of the Bronx as care provider for the 13,500
inmates in New York City correctional facilities. St. Barnabas has been the subject of
frequent criticism, and a criminal investigation by the Manhattan district attorney's office
following several inmate deaths. New York
City has created a strict contract with PHS,
demanding that they agree to stringent
staffing requirements, heightened standards
of care, and steep financial penalties for any
failures. Under the deal, prenatal exams,
dental work and AIDS care must be provided
faster; medications must be provided within
24 hours of when they are first prescribed.
PHS will provide basic care to inmates at
the Rikers Island jails, the Manhattan
Detention Complex and the Vernon C. Bain
floating jail. PHS will deliver care by mental
health professionals, dentists, and other specialties, but treatment for serious injuries and
emergencies will be provided at city-owned
hospitals. (Lipton E. New York Times,
12/1/2000.)

Resources
Safety First: HIV Prevention for Correctional Professionals
A video and brochure entitled "Safety First: Steps You Can Take to Protect Yourself Against
On-the-job Exposure to HIV and Hepatitis" is now available in Spanish and English to help
correctional employees protect themselves from the threat of infection on the job.
To order, fax a request to Agouron at 562.658.2192, or call 800.311.3435.
If you know of other such educational resources, please send information to the attention of
Betsy Stubblefield at HEPP News.
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A
minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through
July 31, 2001. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Which of the following is not considered a positive skin test for
TB infection?
a) >5mm for HIV+ patient.
b) >5mm for a patient with a history of TB contact.
c) >10mm for HIV- patient
d) increase less than 5mm from previous PPD.
e) all of the above are positive skin tests for infection.
2. Indicate which of the following sentences are true?
a) All inmates should be screened for TB signs or symptoms
at intake.
b) Inmates known to have HIV infection should have a chest
radiograph as part of the initial screening, regardless of their
TST status
c) Tuberculin skin tests (TST) should be administered to all
prisoners who have not had a previous documented positive
skin test result.
d) a and b.
e) All of the above
f) None of the above
3. Which of the following antiretrovirals may be acceptable for
co-administration with rifampin?
a) Nelfinavir (NFV, Viracept)
b) Delavirdine (DLV, Rescriptor)
c) Efavirenz (EFV, Sustiva)
d) Indinavir (IDV, Crixivan)
e) a and b
f) All of the above.
4. Which of the following antiretrovirals is not recommended for
co-administration with rifabutin?
a) Saquinavir (SQV, Fortovase, Invirase)
b) Nelfinavir (NFV, Viracept)
c) Amprenavir (AMP, Agenerase)
d) Nevirapine (NVP, Viramune)
e) Delavirdine (DLV, Rescriptor)
f) All of the above.
5. In which of the following situations is hepatotoxicity considered
a threat?
a) patients taking isoniazid or pyrazinamide
b) patients on fluconazole
c) patients with a history of injection drug use
d) a and b
e) a and c
f) All of the above

6. Which of the following statements are true about TB treatment?
a) The initial use of four drug therapy in treating TB is
recommended if the local rate of INH resistance is >4%.
b) Treating TB in co-infected individuals improves can raise CD4
counts and decrease viral load.
c) Malabsorption of antituberculous medications has been
demonstrated to occur in HIV disease and in diabetes.
d) a and b
e) All of the above

HEPP News Evaluation
5 Excellent

4 Very Good

3 Fair

2 Poor

1 Very Poor

1. Please evaluate the following sections with respect to:
educational value

clarity

Main Article

5 4 3 2 1
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HIV 101
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2. Do you feel that HEPP News helps you in your work?
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3. What future topics should HEPP News address?

4. How can HEPP News be made more useful to you?

5. Do you have specific comments on this issue?
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